Given this limitation and the lack of an association between IL-6 and NSE in patients with low-severity cardiac arrest, the brain inflammatory response that can exacerbate HIBI after cardiac arrest is insufficient for determining the neuroprotective effect of tocilizumab. Here, ENO2 is linked to cardiac arrest.